6 suspended. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Suspended 6 |
| Phase 1 | 2 | Suspended 2 |
| Phase 3 | 1 | Suspended 1 |
Follow Congenital Abnormalities: new trials by email Literature Review of Congenital Abnormalities trials Research Report on Congenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma Rituximab, Zanubrutinib, Cyclophosphamide - Diffuse Large B Cell Lymphoma, CD79A Gene Mutation | Phase 2 | Suspended | Henan Cancer Hospital | 59 | 2020-12-25 | 2025-04-25 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) ASN-002 - Basal Cell Carcinoma in Basal Cell Nevus Syndrome | Phase 1 / Phase 2 | Suspended | Ascend Biopharmaceuticals Ltd | 24 | 2017-12-01 | 2023-02-06 |
| Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants. Intravenous paracetamol, Intravenous ibuprofen - Ductus Arteriosus Patent, Respiratory Distress Syndrome | Phase 2 / Phase 3 | Suspended | University of Padova | 120 | 2017-01-09 | 2019-11-04 |
| A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome STX107 - Fragile X Syndrome | Phase 2 | Suspended | Seaside Therapeutics, Inc. | 16 | 2011-05-01 | 2012-12-20 |
Fragile X Syndrome (2) · Basal Cell Nevus Syndrome (1) · Behavior (1) · Carcinoma, Basal Cell (1) · Cognitive Dysfunction (1) · Ductus Arteriosus, Patent (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1) · Neurobehavioral Manifestations (1) · Premature Birth (1) · Recurrence (1) · Respiratory Distress Syndrome (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Nervous System Diseases (3) · Chromosome Disorders (2) · Genetic Diseases, X-Linked (2) · Hemic and Lymphatic Diseases (2) · Intellectual Disability (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Sex Chromosome Disorders (2) · X-Linked Intellectual Disability (2)
CA-4948 (1) · Cyclophosphamide (1) · Epirubicin (1) · Prednisone (1) · Psilocybin (1) · Rituximab (1) · Vincristine (1) · gusacitinib (1) · venetoclax (1) · zanubrutinib (1)
Ascend Biopharmaceuticals Ltd (1) · Curis, Inc. (1) · Henan Cancer Hospital (1) · Nova Mentis Life Science Corp (1) · Seaside Therapeutics, Inc. (1) · University of Padova (1)
United States (3) · Italy (2) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Poland (1) · Spain (1)
Anna Bar (1) · Clement Leong (1) · David Crowley, MD (1) · Marvin Hausman, MD (1) · Paola Lago, MD (1) · Yanyan Liu, M.D. Ph.D (1) · Zhihua Yao, M.D. Ph.D (1)